Drugs / Spevatamig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05482893 | Mar 2023 → Dec 2027 expected | biliary tract cancer, colorectal cancer, gastroesophageal adenocarcinoma, pancreatic ductal adenocarcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spevatamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05482893 ↗ |
| Known as | PT886 | “Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.” NCT05482893 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068300 ↗ |